Anticipating royalites from Ellavie (menopause treatment) of 15 million a year.
Based on Evamist/Ellavie sales so far, this forecast now looks massively over-optimistic. I'd be surprised if Evamist royalties from KV are as much as $1 million a year. Ellavie (Evamist in the RoW) may do better with better partners, but it seems clear the product isn't a bestseller.
One has to wonder if the forecast Axiron market might not turn out the same way...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.6¢ |
Change
-0.001(5.88%) |
Mkt cap ! $6.524M | |||
| Open | High | Low | Value | Volume |
| 1.6¢ | 1.7¢ | 1.6¢ | $3.711K | 220.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 329402 | 1.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.8¢ | 252359 | 2 |
View Market Depth
| Last trade - 15.57pm 30/06/2025 (20 minute delay) ? |
| ACR (ASX) Chart |